Your browser does not support iframes.
Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Oncolytics Biotech, Inc.
(NQ:
ONCY
)
2.750
USD
+0.030 (+1.10%)
Official Closing Price
/ Updated:
8:10 PM EDT, May 22, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
2.970
Bid (Size)
2.720 (200)
Ask (Size)
2.750 (400)
Prev. Close
2.720
Today's Range
2.640 - 3.060
52wk Range
1.600 - 4.930
Shares Outstanding
84,758,818
Dividend Yield
N/A
Top News
More News
ONC.CA Makes Bullish Cross Above Critical Moving Average
Today 10:48 EDT
In trading on Wednesday, shares of Oncolytics Biotech Incorporated (ONC) crossed above their 200 day moving average of $2.94, changing hands as high as $3.15 per share. Oncolytics Biotech Incorporated...
Read More
category
Dividends
from
Dividend Channel
Oncolytics cancer drug meets mid-stage trial goal, shares rise
Today 9:44 EDT
May 22 (Reuters) - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with...
Read More
category
companyNews
from
Reuters: Company News
More News
Read More
StreetInsider.com Pre-Open Movers 5/22: (ZLC) (SKS) (TOL) Higher; (UAN) (TGT) (SODA) Lower (more...)
Today 9:36 EDT
from
StreetInsider.com News Articles
Oncolytics Announces First Stage of Metastatic Melanoma Phase 2 Trial Meets Primary Endpoint
Today 6:41 EDT
category
Contracts
,
Management
,
Benzinga
, and 4 more.
from
Latest Articles from Benzinga.com
Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
Today 6:37 EDT
from
StreetInsider.com News Articles
Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
Today 6:30 EDT
from
PR Newswire
Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care Conference
May 14, 2013
from
PR Newswire
Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of Shareholders
May 10, 2013
from
PR Newswire
Oncolytics Biotech (ONCY) Posts Q1 Loss of 8c/Share
May 09, 2013
from
StreetInsider.com News Articles
Oncolytics Biotech® Inc. Announces First Quarter 2013 Results
May 09, 2013
from
PR Newswire
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.